{"id":2698,"date":"2018-07-10T22:30:14","date_gmt":"2018-07-10T17:00:14","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2698"},"modified":"2021-07-24T12:57:00","modified_gmt":"2021-07-24T07:27:00","slug":"notizia-67","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-67","title":{"rendered":"Notizia"},"content":{"rendered":"

Arming antibiotics with a vaccination-like immune response<\/strong><\/p>\n

Harnessing\u00a0the ability\u00a0of the body\u2019s\u00a0immune system\u00a0has already\u00a0well-tried\u00a0to be effective in treating cancer. Marcos Pires, Ph.D., a Lehigh associate professor of biochemistry performed a test on it. To make it worse, these\u00a0microorganism\u00a0perpetually\u00a0evolve, rendering antibiotics inefficient. Some scientists\u00a0are\u00a0making an attempt\u00a0to tackle\u00a0the additional\u00a0protecting\u00a0layer on\u00a0gram-negative microorganisms. In their recent\u00a0analysis, they recruited an\u00a0antibody\u00a0to focus on\u00a0BamA,\u00a0a protein\u00a0that builds the outer wall of\u00a0gram-negative\u00a0microorganism.<\/p>\n

PIRE\u2019s experiment on immune response<\/strong><\/p>\n

Pires\u2019 team assembles its therapy by combining polymyxin B to the lipid A in the surface of Gram-negative pathogens\u2014with antigenic epitopes that attract antibodies. Lehigh Prof. Wonpil Im\u2019s lab, which uses computational biophysics to understand antibiotics\u2019 interaction with bacterial membranes, the team was also able to model how the bacteria\u2019s surface could affect immune system activation. The result? \u201c[A] compound that both directly kills bacteria and at the same time induces an immune response. \u201cWith this one-two punch against these difficult to kill bacteria, we believe there is great potential for in vivo testing to evaluate them further”.<\/p>\n

Finnish drugmaker orion pharma\u2019s amyotrophic lateral sclerosis drug <\/strong><\/p>\n

Finnish drugmaker Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.Orion\u00a0said\u00a0it plans to enroll 450 subjects in\u00a0the\u00a0placebo-controlled trial\u00a0at sites in Europe, North America and Australia, with patients taking the drug for a year to see if it can slow down the respiratory difficulties that are the usual cause of death in ALS.<\/p>\n

European experiments on lateral sclerosis drug <\/strong><\/p>\n

European biotech, France\u2019s AB Science provisionally turned down its masitinib\u00a0drug for ALS in Europe in April, phase 2\/3 trial that showed efficacy at the highest dose used wasn\u2019t sufficient to support approval. Other players in the field include Biogen and Ionis, which have a SOD1-targeting antisense drug called BIIB067 in phase 1\/2 trials,\u00a0Amylyx\u00a0with AMX0035 in phase 2 & new startup\u00a0QurAlis. Another company active in this area is\u00a0Brainstorm Cell Therapeutics, which has stem cell-based\u00a0NurOwn\u00a0in phase 3 for ALS after showing a benefit in mid-stage testing.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Arming antibiotics with a vaccination-like immune response Harnessing\u00a0the ability\u00a0of the body\u2019s\u00a0immune system\u00a0has already\u00a0well-tried\u00a0to be effective in treating cancer. Marcos Pires, Ph.D., a Lehigh associate professor of biochemistry performed a test on it. To make it worse, these\u00a0microorganism\u00a0perpetually\u00a0evolve, rendering antibiotics inefficient. Some scientists\u00a0are\u00a0making an attempt\u00a0to tackle\u00a0the additional\u00a0protecting\u00a0layer on\u00a0gram-negative microorganisms. In their recent\u00a0analysis, they recruited an\u00a0antibody\u00a0to focus […]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1118,204,349,1261,706,1183],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-2698","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-business-research","tag-delveinsight","tag-latest-pharma-news","tag-pharma-consulting","tag-pharmaceutical-industry","tag-pharmaceutical-news","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nNotizia- Latest pharmaceutical industry news by Delveinsight<\/title>\n<meta name=\"description\" content=\"Pires\u2019 team assembles its therapy by combining polymyxin B to the lipid A in the surface of Gram-negative pathogens\u2014with antigenic epitopes that attract antibodies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-67\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia- Latest pharmaceutical industry news by Delveinsight\" \/>\n<meta property=\"og:description\" content=\"Pires\u2019 team assembles its therapy by combining polymyxin B to the lipid A in the surface of Gram-negative pathogens\u2014with antigenic epitopes that attract antibodies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-67\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-10T17:00:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia- Latest pharmaceutical industry news by Delveinsight","description":"Pires\u2019 team assembles its therapy by combining polymyxin B to the lipid A in the surface of Gram-negative pathogens\u2014with antigenic epitopes that attract antibodies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-67","og_locale":"en_US","og_type":"article","og_title":"Notizia- Latest pharmaceutical industry news by Delveinsight","og_description":"Pires\u2019 team assembles its therapy by combining polymyxin B to the lipid A in the surface of Gram-negative pathogens\u2014with antigenic epitopes that attract antibodies","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-67","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-07-10T17:00:14+00:00","article_modified_time":"2021-07-24T07:27:00+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-67","url":"https:\/\/www.delveinsight.com\/blog\/notizia-67","name":"Notizia- Latest pharmaceutical industry news by Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-67#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-67#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-07-10T17:00:14+00:00","dateModified":"2021-07-24T07:27:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pires\u2019 team assembles its therapy by combining polymyxin B to the lipid A in the surface of Gram-negative pathogens\u2014with antigenic epitopes that attract antibodies","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-67"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-67#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 10, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 10, 2018 10:30 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2698"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2698\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2698"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2698"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}